Thanks for that clarification, and for the welcome. Glad to be here.
So now my question is, why would a SOC be limited to the single (coformulation) drug as opposed to the 2 drugs that make up that coformulation? We often see that inpatients in a hospital who usually take a coformulation drug end up on the separate components while in hospital, simply because they are the cheaper option.
If the answer is that the coformulation is potentially a lot safer because of the coformulation itself, and that this cannot be achieved by taking the 2 things together as separate drugs, then I understand the argument. But if it is simply a matter of a certain drug combination, then coformulation is not necessarily going to be the SOC and therefore a medico could not be held to only prescribe in that manner for fear of deviating from the SOC.
I am assuming in advance that it is the potential of the coformulation itself that is the winner here, and at present the 2 drugs are the only versions of themselves and therefore ripe to get into bed together.
- Forums
- ASX - By Stock
- RAC
- Ann: Expanded Heart Protection Discovery for Zantrene
Ann: Expanded Heart Protection Discovery for Zantrene, page-181
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M |
Open | High | Low | Value | Volume |
$1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9216 | $1.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.47 | 7767 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 711 | 1.405 |
2 | 5750 | 1.400 |
1 | 2499 | 1.395 |
1 | 1000 | 1.380 |
2 | 8384 | 1.370 |
Price($) | Vol. | No. |
---|---|---|
1.465 | 7767 | 2 |
1.480 | 3000 | 1 |
1.510 | 687 | 1 |
1.545 | 2040 | 1 |
1.550 | 5000 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |